122results about How to "Ability to inhibit invasion" patented technology

The invention discloses an siRNA of a targeted long-chain noncoding RNA DDX11-AS1 and applications thereof in liver cancer treatment. Through designing and synthesizing the siRNA of the DDX11-AS1 andtransfecting a liver cancer cell line with the siRNA, it is proved that the siRNA can targetedly inhibit expression of the DDX11-AS1, can significantly suppress liver cancer cell proliferation, invasion and migration and can induce liver cancer cell apoptosis. A novel target point for research and development of a liver cancer treatment medicine is provided.

The invention relates to a ursolic acid-aspirin conjugate shown in a formula (I) and application thereof in preparing drugs for preventing tumor metastasis. In vivo experiments verify that the ursolic acid-aspirin conjugate provided by the invention has a remarkable inhibitory effect on adhesion, migration, invasion and the like of tumor cells. in vivo animal experiments verify that the ursolic acid-aspirin conjugate can be used for reducing experimental pulmonary metastasis of 4T1 breast cancer of a rat and showing a relatively good tumor metastasis resisting effect. The ursolic acid-aspirin conjugate provided by the invention can be applied to preventive drugs for tumor metastasis, thereby providing novel selection for developing new drugs for tumor metastasis and preventing postoperative retransfer of malignant tumors. The formula (I) is shown in the description.

The invention provides a fusion protein formed by the combination of urokinase-type plasminogen activator a chain and melittin, the preparation method thereof, and the application of the fusion protein in tumor treatment.

The invention discloses polypeptide used for inhibiting oral squamous cell carcinoma migration and invasion capacities and application thereof. The polypeptide has an amino acid sequence as shown in SEQ ID NO.1. In addition, the invention further discloses a pharmaceutic preparation which can inhibit oral squamous cell carcinoma migration and invasion capacities. The pharmaceutic preparation is prepared from the polypeptide disclosed by the invention and pharmaceutic preparation acceptable auxiliaries. The pharmaceutic preparation can be a capsule, a tablet, an injection or a spray. Accordingto the invention, multiple experimental technologies, such as cell proliferation experiment, scratching experiment and Transwell invision experiment, prove that the novel polypeptide disclosed by theinvention has an inhibiting effect on oral squamous cell carcinoma migration and invasion capacities. The provision of the polypeptide provides an effective technological means for treating oral squamous cell carcinoma.

The invention discloses a genetic group for molecular subtyping of medulloblastoma. The genetic group is formed on one or more of 32 genes in total. The invention further discloses a kit for molecularsubtyping of medulloblastoma and use of the genetic group in the preparation of a reagent for molecular subtyping of medulloblastoma. Besides, the invention further provides use of an SNCA gene for diagnosis or as a diagnosis marker of 4-type medulloblastoma.

An anti-GCC nucleic acid, a preparation method thereof, an immune cell having the nucleic acid, and an application thereof are provided. The anti-GCC nucleic acid at least includes: a Leader nucleotide sequence, a GCC single chain antibody nucleotide artificial sequence, a CD8 hinge region nucleotide sequence, a transmembrane-stimulation structural domain nucleotide sequence, a CD3[zeta] signal transduction region nucleotide sequence, a self-lytic peptide T2A nucleotide sequence, a chemotactic factor IL7 nucleotide sequence and a chemotactic factor CCL19 nucleotide sequence. The anti-GCC nucleic acid can improve the pertinence of the immune cell and reduce the damage on non-tumor cells, thereby improving effectiveness and safety.

The invention provides application of AKR1C1 protein. The product comprises a product for diagnosing lung cancer and predicting lung cancer metastasis by RT-PCR, real-time quantitative PCR, immunodetection, hybridization in situ or gene chip, and is used for preparing a product for diagnosing lung cancer and preparing a medicine for treating lung cancer. Overexpressed AKR1C1 protein can be used for remarkably improving in-vivo metastasis of lung cancer cells and remarkably enhancing in-vitro metastasis and invasion capacity of lung cancer cells, and AKR1C1 can be used for remarkably inhibiting the in-vitro metastasis and invasion capacity of lung cancer cells by RNA interference suppression. The AKR1C1 protein can be used as specific marker protein for diagnosing lung cancer, predicting lung cancer metastasis and prognosing, so that lung cancer diagnosis can be accurately and quickly performed, the accuracy for diagnosing lung cancer and predicting lung cancer metastasis can be improved, and a new treatment target and new effective medicine are provided to lung cancer prevention and treatment.

The invention discloses a long chain noncoding RNA marker for auxiliary diagnosis of colorectal cancer (CRC). Long chain noncoding RNA is HOTAIR; auxiliary diagnosis or prediction of patient conditiondevelopment of the CRC can be realized by detecting expression quantity of the long chain noncoding RNA; differentiation, infiltration depth, proliferation and metastasis conditions of the CRC can bepredicted by monitoring expression conditions of p21 and a value of judging prognosis is realized. Expression level of LncRNA HOTAIR gene can be detected by RT-qPCR, real-time quantitative PCR, immunodetection, in-situ hybridization, chip or a high-throughput sequencing platform; meanwhile, the invention also discloses silencing HOTAIR which can obviously inhibit the proliferation, migration andinvasion abilities of CRC cells, reduce the expression of PCNA, Ki67, cyclin E and CDK2 and medicate expression increase of p21. The invention provides a molecular marker for the CRC and provides theoretical basis for mechanism research and clinical individualized therapy of the CRC; a brand-new treatment strategy can be provided for clinically treating the CRC by monitoring the expression of theLncRNA HOTAIR in the CRC.

The invention discloses a medicine targeting KTN1 to treat skin squamous cell carcinoma. An inventor uses an EGFR (epidermal growth factor receptor) highly-expressed cell strain A431 with the skin squamous cell carcinoma characteristic as an experiment object; after proofing by an experiment, the targeting reduction of KTN1 can inhibit the expression of the EGFR which influences the proliferation, transfer and invasion ability of tumor cells, so as to finally improve or treat the skin squamous cell carcinoma.

The invention discloses application of MLLT11 as a specific marker in preparation of a medicine for diagnosing and treating bladder cancer. The invention further provides a kit for detecting the bladder cancer. The bladder cancer diagnosis kit comprises an antibody specifically combined with the MLLT11 protein. The invention further discloses application of an inhibitor of MLLT11 gene expression in preparation of a medicine for treating the bladder cancer.

The invention discloses an ASO for targeting long-chain non-coding RNA DDX11-AS1 and a kit and application thereof in treatment of liver cancer. By designing and synthesizing the ASO for targeting theDDX11-AS1, transfecting the ASO into a liver cancer cell line and detecting the proliferation, cell growth cycle, migration ability and invasion ability of liver cancer cells, it is confirmed that the ASO can significantly affect the occurrence and development of liver cancer by inhibiting the expression of the DDX11-AS1. A new drug development direction and target are provided for the treatmentof liver cancer.

The invention provides application of epigallocatechin gallate (EGCG) in preparation of a targeted drug for inhibiting estrogen receptor (ER)-alpha 36. Biological experiments prove that the EGCG can remarkably inhibit the proliferation of tumor cells with high expression of ER-alpha 36, thus arresting a cell cycle at the G1 period, inhibiting cell migration and invasion abilities and inducing the occurrence of apoptosis. The EGCG is clear in target function, and is especially obvious in an inhibiting effect for tumor cells with abnormal expression of the ER-alpha 36. The EGCG can be used as an ER-alpha 36 specific targeting inhibitor for playing a role of inhibiting the cells with the abnormal expression of the ER-alpha 36. The application of the EGCG provides a new effective drug for the development of personalized treatment of clinical targeting ER-alpha 36 abnormality.

The invention relates to an imidazole derivative containing an indazole structure as well as a preparation method and application of the imidazole derivative, and belongs to the technical field of medicine synthesis. The imidazole derivative disclosed by the invention is an imidazole compound containing an indazole structure as shown in a structural formula (I) and pharmaceutically acceptable saltor hydrate thereof. The imidazole derivative containing the indazole structure has inhibitory activity on transforming growth factor beta1 receptor kinase (ALK5), can inhibit a TGF -beta induced EMT-like process, has a potential anti-cancer effect on malignant glioma, and can be used for treating human glioma related to an epithelial-mesenchymal transition (EMT)-like process.

The present invention relates to the field of medicine, in particular to regulators for regulating the invasion behavior of glioma stem cells. The application of tumor stem cell invasion inhibitor; the expression of miRNA-20a in GSC was significantly higher than that in GC, and the expression of TIMP-2 in GSC was significantly lower than that in GC regardless of mRNA level or protein level; the inhibitor of miRNA-20a can significantly inhibit Invasion ability of GSC; after inhibiting the expression of miRNA-20a, the expression of TIMP-2 mRNA level and protein level was significantly increased, and the luciferase reporter gene experiment confirmed that miRNA-20a can not only negatively regulate the expression of TIMP-2, but also through and The 3'UTR of TIMP-2 directly regulates the expression of TIMP-2.

The invention belongs to the field of nanomedicine and biomedicine, and discloses a preparation method and application of highly nucleus-targeted anti-tumor nanomedicine. According to the preparationmethod and the application of the highly nucleus-targeted anti-tumor nanomedicine, a polypeptide with nucleus targeting ability and graphite powder are subjected to blending and ball milling, and polypeptide functionalized graphene (TG) with high tumor targeting ability and nucleus targeting ability is prepared under normal temperature and pressure. Furthermore, carboxyl group is introduced into the TG by using an acetic acid plasma technology, and the anti-tumor drug mitomycin C (MMC) is loaded on the TG. The prepared anti-tumor nanomedicine MMC-TG has good tumor cell nucleus targeting ability and can highly selectively target tumor cells. The tumor killing rate is 95% or above, but at the same time, the anti-tumor nanomedicine MMC-TG has little damage to normal cells. Experimental results confirm that the developed nanomedicine first plays a role in the nucleus, and has efficient tumor cell nucleus targeting ability, tumor killing ability and tumor metastasis inhibiting ability.

The invention belongs to the technical field of biological medicines, and relates to a colorectal cancer diagnosis marker and a treatment target and application thereof. The invention firstly providesthat LINC02474 can be used as the colorectal cancer diagnosis marker and the treatment target, and provides a new thought for diagnosis and treatment of colorectal cancer. Researches show that compared with normal control, LINC02474 is remarkably up-regulated in tumor tissues of a patient with colorectal cancer, and the biomarker provided by the invention has relatively high accuracy. Results show that interfering LINC02474 can inhibit migration and invasion abilities of colorectal cancer cells, and prove that LINC02474 plays a role in promoting cancer genes in occurrence and development of colorectal cancer, provides a new thought for clinical treatment of colorectal cancer, and is expected to obtain a diagnosis and treatment scheme which is more acceptable to patients and is clinicallyfeasible.

The invention belongs to the field of biological medicines, and particularly relates to a medicinal composition containing effective amount of FTY720 and cis-platinum for treating esophagus cancer and application thereof in preparation of medicines or health products for inhibiting proliferation and invasion of esophagus cancer cells and promoting esophagus cancer cell apoptosis. Tests prove that after FTY720 and cis-platinum are combined, the medicinal effect is synergized, the cis-platinum is promoted to induce apoptosis of esophagus cancer cells, the effect of cis-platinum for inhibiting invasion of esophagus cancer cells can be reinforced, and the toxin of cis-platinum for a human body can be reduced. The medicinal composition accords with modern medical researching theory, and provides more administration choice for clinical medical treatment of esophagus cancer.

The invention belongs to the technical field of biology, and particularly relates to endothelial cell culture solution. The endothelial cell culture solution comprises a basic culture medium DMEM (dulbecco modified eagle medium), human platelet lysate, L-glutamine, vitamin C, laminin 10, laminin 11, fibronectin, penicillin and streptomycin. The endothelial cell culture solution has the advantages that a pH (potential of hydrogen) value of the endothelial cell culture solution is 6.8-7.0, and the osmotic pressure of the endothelial cell culture solution is 310 mOsm / kg; endothelial cells cultured by the endothelial cell culture solution are high in adherence and proliferation speed, purity, migration capacity and lumen formation rate, invasion effects of the endothelial cells can be inhibited, and accordingly the endothelial cell culture solution is a perfect endothelial cell culture system.

Belonging to the field of gene therapy, the invention discloses application of HOXA9 gene in preparation of drugs for treatment of cutaneous squamous cell carcinoma (CSCC). The inventor and the whole team carry out two years of experimental study, adopt cutaneous squamous cell carcinoma characteristic cell line A431 as the experimental object, and perform experiments to find that targeted up-regulation of HOXA9 can inhibit the tumor cell proliferation, migration and invasion ability, also can inhibit tumor cell glycolysis, and ultimately improve or treat cutaneous squamous cell carcinoma. The invention provides a new method for treatment of CSCC on the basis of maximum guarantee of complete organ functions and beautiful appearance, and the method can overcome the shortcomings of the existing technology and has great significance.

The invention discloses a composition for substituting fructus xanthii to prepare a glioma treatment medicine and a measuring method. The composition composed of neochlorogenic acid, chlorogenic acid,xanthiside, 1,5-dicaffeoylquinic acid and 4,5-dicaffeoylquinic acid basically can substitute an inhibitory effect of the fructus xanthii on mTOR gene expression equivalently, wherein the compositionand the fructus xanthii have equivalent strength; the composition can be used for equivalently substituting the fructus xanthii to prepare an mTOR gene expression inhibitor. Those skilled in the art know that inhibition of the mTOR gene expression can effectively inhibit proliferation of glioma cells (miRNA-99b negatively regulates ability of mTOR for inhibiting invasion of glioma cells. Chinese Pharmacological Bulletin, April 2018, Vol. 34, No. 4); therefore, the composition can be used for equivalent substitution of the fructus xanthii to prepare the glioma treatment medicine.

The invention provides a miRNA molecule, the base composition of which is SEQ ID NO. 1 or SEQ ID NO.1 and SEQ ID NO.2 or SEQ ID NO.3 or SEQ ID NO.4 or SEQ ID NO.10 or the base composition of which is SEQ ID NO. 1 or SEQ ID NO. 1 and SEQ ID NO. 2 or SEQ ID NO. 3 or SEQ ID NO. 4 and which contains a modified nucleotide analogue, and the modified nucleotide analogue is glycosyl-modified or backbone-modified or base-modified or terminal-modified nucleotide. A medicinal composition for treating tumors, which is prepared from the miRNA molecule, can effectively inhibit the formation and development of tumors.

The invention relates to application of a reagent for down-regulating RBMS1 expression in preparation of a medicine for treating lung cancer, and belongs to the technical field of diagnostic kits. The invention provides application of a reagent for down-regulating RBMS1 expression in preparation of a medicine for treating lung cancer. The application disclosed by the invention is helpful for realizing the preparation of the medicine for treating the lung cancer.

The invention discloses applications of suppressor of eytokine signaling 2 (SOCS2), and more specifically discloses applications of suppressor of eytokine signaling 2 as a treatment target in preparation of drugs used for treating lung cancer, and applications of suppressor of eytokine signaling 2 as a detection target in preparation of diagnostic reagents of lung cancer. It is found that lung cancer cell propagation is not influenced by SOCS2, it is possible to inhibit migration and invasion capacity of lung cancer cells through inhibition of tumor EMT process, wherein tumor migration and invasion capacity are closely related with tumor course.

The invention discloses a bridge molecule 1-siRNA interference sequence and a fusion expression vector thereof, and belongs to the technical field of biology. A fragment of synthesized bridge molecule 1-siRNA interference sequence can reduce the expression of bridge molecule 1 protein, and generate inhibiting effect on cellular infiltration and diffusion function participated by the bridge molecule 1 protein; and after transfecting a human glioma cell line, the bridge molecule 1-siRNA fusion expression vector can specifically degrade bridge molecules 1mRNA complemented with the fusion expression vector, inhibit in vitro migration capability and chemotactic capability of malignant glioma LN-229 cells, inhibit in vitro adhesive capability and invasion capability of the malignant glioma LN-229 cells, reduce infiltration and diffusion capabilities of tumor cells, and provide a feasible technological measure for gene therapy of tumor.

The invention discloses an endometriosis diagnosis and prognosis marker and an application thereof. The marker is characterized in that the marker is miR-126-5p or BCAR3 (Breast cancer anti-estrogen resistance 3). The BCAR3 is applied to the preparation of a kit used for the diagnosis and / or prognosis evaluation of endometriosis. The BCAR3 is a biomarker for evaluating the risk of the endometriosis disease. The miR-126-5p or BCAR3 recombinant virus vector is applied to the preparation of products with the function of inhibiting endometriosis. The miR-126-5p or BCAR3 recombinant virus vector isused for preparing medicaments for preventing and / or treating endometriosis. The miR-126-5p and BCAR3 provided by the invention can be used as a novel biomarker to be applied to diagnosis and / or prognosis evaluation of endometriosis; and the corresponding miR-126-5p agomir and BCAR3 recombinant lentiviral vector can be used as a novel medicament, and have potential prevention and treatment valuesfor endometriosis.

The present invention discloses a siRNA molecule for human FOXC1 gene expression inhibition, and an application thereof, and belongs to the field of molecular biology. The siRNA has the following sequence that: the sense strand is 5'-CGGACAAGAAGATCACCCTtt-3', and the antisense strand is 5'-AGGGTGATCTTCTTGTCCGtt-3'. According to the present invention, the siRNA can be provided for effectively inhibiting human FOXC1 gene expression, significantly inhibiting cell proliferation and clone capacity and cell migration and invasion capacity of larynx squamous cell carcinoma cell lines such as Hep-2 and TU-177, and preparing FOXC1-targeting anti-larynx cancer drugs.

The invention discloses composition for replacing radix bupleuri to prepare a glioma treatment medicine and a determination method of the composition. The composition consisting of saikosaponins F, G,C, A and D can basically equivalently replace the inhibition effect of the radix bupleuri to expression of an mTOR gene and has the same intensity with the radix bupleuri. The composition can equivalently replace the radix bupleuri to prepare an mTOR gene expression inhibitor. The skilled in the art know that inhibition of the expression of the mTOR gene can effectively inhibit proliferation of glioma cells (miRNA-99b negatively regulates the invasion ability of mTOR in inhibiting glioma cells, China Pharmacology General, volume 34, number 4, in 4, 2018), so that the composition can be used for equivalently replace the radix bupleuri to prepare the glioma treatment medicine.

The invention discloses a miR-182 transcription inhibition factor and an application of a miR-182 transcription inhibition factor to osteosarcoma. The miR-182 transcription inhibition factor has a miR-182 transcription inhibition factor sequence SEQ ID NO. The application includes an application to an osteosarcoma cell system, an application to tissues of an osteosarcoma patient, an application to cell proliferation marker genes Ki-67 and PCNA, and an application to a TIAM1 gene in an osteosarcoma cell. According to the application, the expression of the miR-182 in the osteosarcoma cell system and the tissues is remarkably reduced, the over-expression of the miR-182 remarkably inhibits the tumor growth, the level of the miR-182 in regulating and controlling the expression of the cell proliferation markers Ki-67 and PCNA is remarkably improved, the miR-182 in the osteosarcoma cell directly targets the TIAM1 gene, and the miR-182 influences the occurrence, development and deterioration of the osteosarcoma by regulating and controlling the expression of the TIAM1.